Immediate Management of Severe Thrombocytopenia (Platelet Count ≤ 6,000/µL)

Hospital Admission & Specialist Consultation

• Admit any patient with a platelet count < 10,000/µL regardless of bleeding because the risk of spontaneous serious hemorrhage, including intracranial bleed, is high. 1
• Admit patients with platelet counts < 20,000/µL who are asymptomatic or have only minor mucocutaneous bleeding rather than managing them as out‑patients. 2
• Arrange a hematology consultation within 24–72 hours of diagnosis to guide further evaluation and therapy. 2

Bleeding Precautions

• Implement immediate bleeding‑precaution measures: avoid intramuscular injections, minimize venipunctures, use a soft toothbrush, and discontinue NSAIDs and antiplatelet agents. 3
• Control blood pressure aggressively and consider menstrual suppression when appropriate to reduce bleeding risk. 3

Diagnostic Workup

Confirmation of True Thrombocytopenia

• Review a peripheral blood smear to verify true thrombocytopenia and to look for schistocytes, platelet clumping, or abnormal cells that may indicate specific etiologies. 4, 5

Baseline Laboratory Panel

• Obtain a complete blood count with differential to differentiate isolated thrombocytopenia from pancytopenia. 4
• Perform a coagulation screen (PT/INR, aPTT, fibrinogen by Clauss assay) to distinguish consumptive coagulopathy from isolated platelet loss. 4, 6
• Measure D‑dimer to assess for thrombotic microangiopathy or disseminated intravascular coagulation. 4, 5
• Order LDH, haptoglobin, indirect bilirubin, and reticulocyte count to evaluate for hemolysis suggestive of TTP or other microangiopathic processes. 5

History Elements Guiding Etiology

• Recent COVID‑19 vaccination (5–42 days) should raise suspicion for vaccine‑induced immune thrombocytopenia and thrombosis (VITT). 4, 6
• Recent heparin exposure warrants evaluation for heparin‑induced thrombocytopenia (HIT), which occurs in up to 1 % of patients receiving unfractionated heparin. 5
• Recent infections (e.g., HIV, hepatitis C, EBV, CMV, dengue) are important triggers of severe thrombocytopenia. 5

Life‑Threatening Etiologies & Immediate Interventions

Thrombotic Thrombocytopenic Purpura (TTP)

• Send ADAMTS13 activity and inhibitor titers immediately, but do not delay treatment while awaiting results. 5
• If TTP is suspected (pentad of thrombocytopenia, microangiopathic hemolytic anemia, neurologic changes, renal dysfunction, fever), start therapeutic plasma exchange without delay; each hour of postponement increases mortality. 5
• After the first plasma exchange, administer methylprednisolone 1 g IV daily for 3 days. 5

Heparin‑Induced Thrombocytopenia (HIT)

• Discontinue all heparin products immediately, including heparin flushes. 4
• Initiate an alternative non‑heparin anticoagulant (e.g., argatroban or fondaparinux). 4
• Send anti‑PF4 (HIT) antibody testing concurrently. 4

Vaccine‑Induced Immune Thrombocytopenia and Thrombosis (VITT)

• Consider VITT when symptoms begin 5–30 days after a COVID‑19 vaccine and D‑dimer exceeds 4,000 µg/mL (FEU). 4, 6
• Administer IVIG 1 g/kg immediately to neutralize anti‑PF4 antibodies. 4, 6
• Perform same‑day imaging based on clinical suspicion (head CT venogram for cerebral venous sinus thrombosis, abdominal ultrasound for splanchnic thrombosis, CT pulmonary angiography for pulmonary embolism). 4, 6
• If thrombosis is confirmed, treat with non‑heparin anticoagulants (direct oral anticoagulants, fondaparinux, argatroban). 4, 7

Disseminated Intravascular Coagulation (DIC)

• Laboratory pattern: markedly elevated D‑dimer, prolonged PT/aPTT, low fibrinogen, and presence of schistocytes. 5
• Management focuses on treating the underlying trigger (e.g., sepsis, trauma, malignancy). 1

Platelet Transfusion Strategy

Prophylactic Thresholds

• Transfuse prophylactically when platelet count falls < 10,000/µL in the absence of bleeding to prevent spontaneous hemorrhage. 1
• Give 1–2 therapeutic adult platelet units to raise the count above 10,000/µL. 1

Exceptions (When NOT to Transfuse)

• Immune thrombocytopenia (ITP): avoid platelet transfusion unless there is life‑threatening bleeding, because transfused platelets are rapidly destroyed. 8, 3
• TTP: platelet transfusion may exacerbate microvascular thrombosis and is therefore contraindicated. 5

Active Bleeding

• For major bleeding, maintain platelet count > 50,000/µL; for minor bleeding, maintain > 20,000/µL. 1
• In intracranial hemorrhage, target a platelet count ≥ 100,000/µL (American College of Cardiology recommendation). 9

Procedural Thresholds

• Lumbar puncture: transfuse if platelet count < 20,000/µL (strong recommendation). 10
• Major surgery: transfuse if platelet count < 50,000/µL. 1

Etiology‑Specific Treatment

Immune Thrombocytopenia (ITP)

• First‑line corticosteroids: prednisone 1 mg/kg/day or dexamethasone 40 mg daily for 4 days. 8, 2
• IVIG 1 g/kg (1–2 doses over 2 days) for rapid platelet rise within 24 hours, especially when bleeding or urgent procedures are needed. 8, 3
• Combination of prednisone + IVIG is recommended for emergency situations with uncontrolled bleeding. 3
• High‑dose methylprednisolone may be useful in severe, refractory cases. 3

Sepsis‑Related Thrombocytopenia

• Aggressively treat the underlying infection. 1
• Prophylactic platelet transfusion when count < 10,000/µL without bleeding, or < 20,000/µL when there is a significant bleeding risk. 1

Monitoring & Follow‑Up

• Perform daily platelet counts until a stable upward trend is documented. 8
• Serially monitor hemoglobin (for hemolysis), creatinine (renal function), and LDH (tissue injury). 5